Share on StockTwits

Circassia Pharmaceuticals PLC (LON:CIR)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Monday. They currently have a GBX 341 ($5.74) price objective on the stock. Canaccord Genuity’s target price would suggest a potential upside of 17.18% from the company’s current price.

Shares of Circassia Pharmaceuticals PLC (LON:CIR) opened at 286.13 on Monday. Circassia Pharmaceuticals PLC has a 1-year low of GBX 268.00 and a 1-year high of GBX 319.00. The stock has a 50-day moving average of GBX 300. and a 200-day moving average of GBX 302.0.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.